Free Trial
NASDAQ:EVLO

Evelo Biosciences (EVLO) Stock Price, News & Analysis

Evelo Biosciences logo
$0.0015 0.00 (0.00%)
(As of 11/22/2024 ET)

About Evelo Biosciences Stock (NASDAQ:EVLO)

Key Stats

Today's Range
$0.0015
$0.0015
50-Day Range
$0.00
$0.06
52-Week Range
$0.00
$0.59
Volume
570 shs
Average Volume
1,770 shs
Market Capitalization
$28,474.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Receive EVLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

EVLO Stock News Headlines

Automatic Income (from home)
Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…
Evelo Biosciences, Inc. (EVLO)
See More Headlines

EVLO Stock Analysis - Frequently Asked Questions

Evelo Biosciences' stock was trading at $0.0615 at the start of the year. Since then, EVLO stock has decreased by 97.6% and is now trading at $0.0015.
View the best growth stocks for 2024 here
.

Evelo Biosciences, Inc. (NASDAQ:EVLO) posted its earnings results on Wednesday, October, 27th. The company reported ($12.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($10.80) by $1.80.

Evelo Biosciences shares reverse split on the morning of Friday, June 30th 2023. The 1-20 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Evelo Biosciences (EVLO) raised $85 million in an initial public offering on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Evelo Biosciences investors own include Sangamo Therapeutics (SGMO), Fulcrum Therapeutics (FULC), CymaBay Therapeutics (CBAY), Provention Bio (PRVB), VIVUS (VVUS), Meta Platforms (META) and Entasis Therapeutics (ETTX).

Company Calendar

Last Earnings
10/27/2021
Today
11/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EVLO
Fax
N/A
Employees
120
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.92) per share

Miscellaneous

Free Float
18,789,000
Market Cap
$28,474.50
Optionable
No Data
Beta
1.29
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:EVLO) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners